Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Microbix Biosystems Inc > New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(113)
•••
Comment by prophetoffactzon Feb 14, 2024 12:54pm
120 Views
Post# 35880073

RE:RE:RE:RE:New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024

RE:RE:RE:RE:New Press Release - Microbix Reports Record Results for Q1 Fiscal 2024

They expect record revenue ignoring Kinlytic. Given record revenue is  $19.1 and revenue in Q1 was $4.2 million(minus Kinlytic) the next three quarter have to average in excess of approximately $5 million per quarter.



lscfa wrote: Mgmt need to get base business growing...


 

Qtr ending 

Antigen

QAP

DxTM

Royalties/Licensing

Total Revenue

Dec 23

1,953,677

2,248,236

0

4,205,972

8,407,885

Sep 23

2,977,179

1,195,231

0

208,046

4,380,456

Jun 23

2,608,521

1,456,905

0

1,464,726

5,530,152

Mar 23

3,004,730

1,101,684

0

111,910

4,218,324

Dec 22

1,003,807

1,333,503

0

164,762

2,502,072

Sept 22

2,629,901

1,601,900

0

97,300

4,329,101

Jun 22

2,283,621

1,305,896

1,326,410

95,099

5,011,026

Mar 22

1,607,970

1,318,382

1,860,704

93,508

4,880,564

Dec 21

1,766,416

1,149,151

1,817,245

122,787

4,855,599

Sep 21

2,020,861

1,195,545

2,327,600

85,689

5,629,695

Jun 21

2,398,969

1,051,617

1,924,300

76,948

5,451,834

Mar 21

2,524,363

1,495,088

255,000

79,322

4,353,773

Dec 20

2,137,829

962,421

0

57,409

3,157,659

Sept 20

2,151,767

505,898

0

48,067

2,705,732

Jun 20

2,245,912

570,148

0

82,218

2,898,278

Mar 20

2,357,972

425,837

0

90,687

2,874,496

Dec 19

1,946,459

26,114

0

73,775

2,046,348

 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities